...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Epigenetics is proud to announce the appointment Dr. Brad Thompson, PhD to our Board of Directors!

Any buyout deal for Zenith must be at or above  $1.7 Billion Usd which there# 1 peer competitor Constellation Pharma received last last year. Any less would be a massive travesty of shareholder value as zenith as much further ahead clinically in all their trials and   Revenue potential seems much much better than Constellation, but i do have a biased view,  

 

just look at the fact that Pfizer paid $14Billion to Medivation for Xtandi,which was FDA approved, If Zenith to the point of an FDA drug  registration , Look out what Zenith will be worth!!! I could be dreaming but the potentional in a few years is there

Share
New Message
Please login to post a reply